Safety, pharmacokinetic, and functional effects of the Nogo-A monoclonal antibody in amyotrophic lateral sclerosis: A randomized, first-in-human clinical trial

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Meininger, Vincent ^a   Pradat, Pierre François ^a,s   Corse, Andrea ^b   Al Sarraj, Safa ^c   Brooks, Benjamin Rix ^d   Caress, James B ^e   Cudkowicz, Merit ^f   Kolb, Stephen J ^g   Lange, Dale ^h   Leigh, P Nigel ⁱ   Meyer, Thomas ^j   Milleri, Stefano ^k   Morrison, Karen E ^l   Orrell, Richard W ^m,t   Peters, Gary ⁿ   Rothstein, Jeffrey D ^b   Shefner, Jeremy ^o   Lavrov, Arseniy ^p   Williams, Nicola ^p   Overend, Phil ^p   Price, Jeffrey ^p   Bates, Stewart ^p   Bullman, Jonathan ^p   Krull, David ^q   Berges, Alienor ^p   Abila, Bams ^p   Meno Tetang, Guy ^p   Wurthner, Jens ^r   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k G B ROSSI UNIVERSITY HOSPITAL   (Italy)

^l UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ ADDENBROOKE S HOSPITAL   (United Kingdom)

^o State University of New York Upstate Medical University: College of Medicine   (United States)

^p GLAXOSMITHKLINE   (United Kingdom)

^q GLAXOSMITHKLINE   (United States)

^r NOVARTIS PHARMA AG   (Switzerland)

^s INSERM   (France)

^t ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATINE KINASE; DRUG ANTIBODY; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; OZANEZUMAB; PLACEBO; PROTEIN NOGO A; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; MYELIN PROTEIN; PROTEIN NOGO;

ABDOMINAL PAIN; ADULT; AMYOTROPHIC LATERAL SCLEROSIS; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BACKACHE; BLOOD PRESSURE; BRONCHITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DELTOID MUSCLE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART ARREST; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROCEDURAL PAIN; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SKELETAL MUSCLE; UNSPECIFIED SIDE EFFECT; WEAKNESS; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED;

ADMINISTRATION, INTRAVENOUS; AMYOTROPHIC LATERAL SCLEROSIS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYELIN PROTEINS;

EID: 84901297430     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097803     Document Type: Article

References (28)

1. Cleveland DW (1999) From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 24: 515-520.
2. Miller RG, Jackson CE, Kasarskis EJ, England JD, Kalra S, et al (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73: 1218-1226.
3. Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (Online) 3: CD001447.
4. Talbot K (2009) Motor neuron disease: the bare essentials. Pract Neurol 9: 303-309.
5. Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, et al (2005) Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 65: 586-590. (Pubitemid 41170719)
6. Turner MR, Hardiman O, Benatar M, Brooks BR, Chio A, et al (2013) Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol 12: 310-322.
7. Rothstein JD (1996) Therapeutic horizons for amyotrophic lateral sclerosis. Curr Opin Neurobiol 6: 679-687.
8. Pandya RS, Zhu H, Li W, Bowser R, Friedlander RM, Wang X (2013) Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol Life Sci 70: 4729-4745.
9. Bellingham MC (2011) A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 17: 4-31.
10. Schwab ME (2004) Nogo and axon regeneration. Curr Opin Neurobiol 14: 118-124.
11. Schwab ME (2010) Functions of Nogo proteins and their receptors in the nervous system. Nat Rev Neurosci 11: 799-811.
12. Dupuis L, Gonzalez de Aguilar J-L, di Scala F, Rene F, da Tapia M, et al (2002) Nogo provides a molecular marker for diagnosis of amyotrophic lateral sclerosis. Neurobiol Dis 10: 358-365. (Pubitemid 35217587)
13. Jokic N, Gonzalez de Aguilar J-L, Pradat P-F, Dupuis L, Echaniz-Laguna A, et al (2005) Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity. Ann Neurol 57: 553-536.
14. Pradat P-F, Bruneteau G, Gonzalez de Aguilar J-L, Dupuis L, Jokic N, et al (2007) Muscle Nogo-a expression is a prognostic marker in lower motor neuron syndromes. Ann Neurol 62: 15-20. (Pubitemid 47235276)
15. Tågerud S, Libelius R, Magnusson C (2007) Muscle Nogo-A: a marker for amyotrophic lateral sclerosis or for denervation? Ann Neurol 62: 676.
16. Magnusson C, Libelius R, Tågerud S. (2003) Nogo (Reticulon 4) expression in innervated and denervated mouse skeletal muscle. Mol Cell Neurosci 22: 298-307. (Pubitemid 36407593)
17. Askanas V, Wojcik S, Engel WK (2007) Expression of Nogo-A in human muscle fibers is not specific for amyotrophic lateral sclerosis. Ann Neurol 62: 676-677.
18. Wojcik S, Engel WK, Askanas V (2006) Increased expression of Noga-A in ALS muscle biopsies is not unique for this disease. Acta Myol 25: 116-118. (Pubitemid 46579319)
19. Jokic N, Gonzalez de Aguilar JL, Dimou L, Lin S, Fergani A, et al (2006) The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep 7: 1162-1167. (Pubitemid 44660574)
20. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, et al (2004) Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185: 232-240. (Pubitemid 38084849)
21. Weinmann O, Schnell L, Ghosh A, Montani L, Wiessener C, et al (2006) Intrathecally infused antibodies against Nogo-A penetrate the CNS and downregulate the endogenous neurite growth inhibitor Nogo-A. Mol Cell Neurosci 32: 161-173. (Pubitemid 43868104)
22. Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1: 293-299.
23. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurological Sci 169: 13-21. (Pubitemid 29502501)
24. Sanjak M, Salachas F, Frija-Orvoen E, Theys P, Hutchinson D, et al (2010) Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11: 383-388.
25. Great Lakes ALS Study Group (2003) A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 61: 1503-1507.
26. Shefner JM, Watson ML, Simionescu L, Caress JB, Burns TM, et al (2011) Multipoint incremental motor unit number estimation as an outcome measure in ALS. Neurology 77: 235-241.
27. Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, et al (2011) The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med 17: 1652-166.
28. Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, et al (2013) Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 12: 1059-1067.